0001179110-17-006134.txt : 20170420 0001179110-17-006134.hdr.sgml : 20170420 20170420202917 ACCESSION NUMBER: 0001179110-17-006134 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170418 FILED AS OF DATE: 20170420 DATE AS OF CHANGE: 20170420 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics AG CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: C4 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: LEBERSTRASSE 20 CITY: VIENNA STATE: C4 ZIP: 1110 BUSINESS PHONE: 43 (0)1 740 93-0 MAIL ADDRESS: STREET 1: LEBERSTRASSE 20 CITY: VIENNA STATE: C4 ZIP: 1110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HBM Healthcare Investments (Cayman) Ltd. CENTRAL INDEX KEY: 0001232258 STATE OF INCORPORATION: E9 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37558 FILM NUMBER: 17774003 BUSINESS ADDRESS: STREET 1: 2454 WEST BAY ROAD, 3RD FLOOR CITY: GRAND CAYMAN STATE: E9 ZIP: 00000 BUSINESS PHONE: 1 345 946 8002 MAIL ADDRESS: STREET 1: P.O BOX 30852 CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1204 FORMER NAME: FORMER CONFORMED NAME: HBM BIOVENTURES CAYMAN LTD DATE OF NAME CHANGE: 20030512 4 1 edgar.xml FORM 4 - X0306 4 2017-04-18 0 0001641640 Nabriva Therapeutics AG NBRV 0001232258 HBM Healthcare Investments (Cayman) Ltd. GOVERNORS SQUARE, SUITE #4-212-2 23 LIME TREE BAY AVE., WEST BAY GRAND CAYMAN E9 00000 CAYMAN ISLANDS 0 0 1 0 American Depository Shares representing Common Shares 2017-04-18 4 S 0 11822 11.1555 D 2624633 D American Depository Shares representing Common Shares 2017-04-19 4 S 0 11785 11.0678 D 2612848 D American Depository Shares representing Common Shares 2017-04-20 4 S 0 325 11.00 D 2612523 D Each American Depository Share of the Issuer ("ADS") represents one-tenth (1/10th) of a Common Share. The Reporting Person holds both Common Shares and ADSs representing Common Shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of ADSs. The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $11.13 to $11.20. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions ranging from $11.05 to $11.20. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price. /s/ Jean-Marc Lesieur, Managing Director 2017-04-20